Bayer announces start of Phase 2 GenePHIT trial for AB-1002
Bayer AG and its subsidiary Asklepios BioPharmaceutical, Inc. (AskBio), have achieved a significant milestone in the fight against congestive heart failure (CHF) with the randomization ... Read More
Bayer to acquire Asklepios BioPharmaceutical in $4bn deal: A strategic move in gene therapy innovation
In a significant development within the pharmaceutical industry, German pharma giant Bayer has reached an agreement to acquire the US-based clinical-stage gene therapy company Asklepios ... Read More